Labcorp Announces Clinical Availability of Liquid Biopsy Test to Guide Personalized Treatment Plans for Patients with Advanced Solid Tumors

Core Insights - Labcorp has launched Labcorp® Plasma Complete™, a ctDNA-based genomic profiling solution for advanced solid tumors, enabling oncologists to make personalized treatment decisions from a simple blood draw [1][2]. Group 1: Product Features - Labcorp Plasma Complete detects genomic alterations in ctDNA across 521 genes, including single nucleotide variants (SNVs), insertions/deletions (InDels), amplifications, translocations, and microsatellite instability [2]. - The test provides a reportable range with a variant allele frequency as low as 0.1% and a specificity greater than 99.99%, allowing for precise detection of tumor-specific biomarkers [4]. Group 2: Clinical Application - The solution is designed to guide targeted treatment decisions, especially when tissue-based testing is not feasible, thus expanding Labcorp's oncology portfolio [2][3]. - Labcorp Plasma Complete is validated in a CAP-accredited and CLIA-certified laboratory, ensuring clinical accuracy and reliability [4]. Group 3: Support for Oncologists - The test simplifies the interpretation of complex genomic data through clear and comprehensive clinical reports, reducing the burden on oncologists [3]. - Integration with Labcorp's broad cancer diagnostic portfolio aids in guiding treatment decisions across all stages of cancer care [3]. Group 4: Research and Development - Labcorp Plasma Complete remains available for biopharmaceutical research, in addition to its clinical applications [4]. - The company has supported over 75% of new drugs and therapeutic products approved by the FDA in 2024, showcasing its significant role in drug development [5].